Reason for request

Re-assessment of the improvement in actual benefit

Moderate clinical added value in first-line treatment of unresectable malignant pleural mesothelioma

  • ALIMTA has marketing authorisation, in combination with ciscplatin for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.
  • It is the standard treatment for this disease. 


Clinical Benefit



Clinical Added Value



Therapeutic use


Contact Us

Évaluation des médicaments